Regeneron stock weighs Q3 growth and broader Sanofi alliance

Published on 11/07/2026 at 12:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock remains in focus after strong third-quarter growth and a broader Sanofi antibody alliance. Investor conferences are scheduled next.

What shaped the week

Third-quarter revenue rose 36 percent to 5.1 billion US dollars, while non-GAAP diluted earnings per share increased 70 percent to 20.07 US dollars.
Regeneron expanded its Sanofi alliance to four next-generation, long-acting antibodies and expects a 1.0 billion US dollar upfront payment in fourth-quarter collaboration revenue.
Management will present at healthcare investor conferences in London and the United States from November 17 through December 2.

Regeneron, US75886F1075, Illustration mit AI erstellt.

Regeneron Pharmaceuticals reported strong third-quarter growth on Friday, October 30, while expanding its antibody alliance with Sanofi. The company also set dates for three upcoming healthcare investor conferences, keeping its pipeline and partnership strategy in focus for investors.

Growth and partnership expansion

In its October 30 release, Regeneron said third-quarter revenue rose 36 percent year over year to 5.1 billion US dollars. GAAP diluted earnings per share increased 35 percent to 18.45 US dollars, while non-GAAP diluted earnings per share rose 70 percent to 20.07 US dollars.

Sanofi collaboration revenue reached 2.724 billion US dollars, supported by higher antibody profits and the full repayment of the Sanofi Development Balance in the second quarter. Regeneron said its expanded alliance with Sanofi covers four next-generation, long-acting antibodies. The company received a 1.0 billion US dollar upfront payment that it expects to recognize as collaboration revenue in the fourth quarter, with potential future milestones of up to 7.0 billion US dollars.

Investor events set the next dates

Regeneron announced on Monday, November 2, that management will participate in the Jefferies Global Healthcare Conference in London on November 17, the Evercore Healthcare Conference on December 1 and Citi's Global Healthcare Conference on December 2. The company announcement said the sessions will be webcast and that replays and transcripts will remain available for at least 30 days.

Regeneron stock traded at 811.60 euros on Lang & Schwarz at 12:00 CET on Saturday, November 7, 2026. The quote provides a current trading reference, while the company's operating update and the expanded Sanofi relationship remain the principal business developments for the week.

Investors can access the real-time quote of Regeneron stock for the latest trading reference.